Mavacamten

Another Name
Camzyos,MYK-461,Monograph,a622047
Indications
Obstructive Hypertrophic Cardiomyopathy (oHCM).
Reg No
09L1198/24
Inspection No
2128-24
dosage form:Capsules
Specs:2.5mg * 60 Capsules
Indate:2 Years
Date:2024-12-21 Views:1298

COMPOSITION:

Each LuciMava capsule contains Mavacamten ………………….2.5mg.

INDICATIONS

LuciMava is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.

DOSAGE AND USE:

The recommended starting dose is 5 mg orally once daily without regard to food; allowable subsequent doses with titration are 2.5 mg, 5 mg, 10 mg, or 15 mg orally once daily. The maximum recommended dose is 15 mg orally once daily.Refer the full Prescribing information for detail instructions.

Capsules should be swallowed whole & not chewed or crushed.

STORAGE:

In a dry place and store at 20℃ to 25℃.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNINGS:

Keep medicine out of reach of Children. Do not administer LuciMava during Pregnancy and Lactation.

Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/mavacamten/

Related News